Wan, Y. Louise http://orcid.org/0000-0003-1441-6050
Sapra, Puja
Bolton, James
Chua, Jia Xin
Durrant, Lindy G.
Stern, Peter L.
Funding for this research was provided by:
Wellcome Trust (101714/Z/13/Z)
Article History
First Online: 22 July 2019
Change Date: 3 October 2019
Change Type: Correction
Change Details: The article Combination Treatment with an Antibody–Drug Conjugate (A1mcMMAF) Targeting the Oncofetal Glycoprotein 5T4 and Carboplatin Improves Survival in a Xenograft Model of Ovarian Cancer, written by Y. Louise Wan, Puja Sapra, James Bolton, Jia Xin Chua, Lindy G. Durrant and Peter L. Stern, was originally published under a CC BY-NC 4.0 license, but has now been made available under a CC BY 4.0 license.
Compliance with Ethical Standards
:
: This project was funded by the Wellcome Trust as part of a Wellcome Trust Clinical Research Fellowship (101714/Z/13/Z).
: Puja Sapra is an employee of Pfizer Inc. Peter L. Stern has received speaker honoraria from Pfizer. Y. Louise Wan, James Bolton, Jia Xin Chua and Lindy G. Durrant have no conflicts of interest that are directly relevant to the content of this article.
: All animal work has been conducted in accordance with ethical standards and according to the Declaration of Helsinki and national and international guidelines and has been approved by the Ethics Regulatory Committee at the Cancer Research UK Manchester Institute. Patient samples and data were collected and analysed with the approval of the Derby Royal Hospital Ethics Committee and the Nottingham Research Ethics Committee.